Symbol | Exchange | Currency |
|---|
Catalyst Biosciences (CBIO) has won the FDA’s Orphan Drug Designation for Marzeptacog alfa as a treatment for Factor VII Deficiency, a rare hereditary bleeding disorder.According...
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that a fireside chat including members of its executive...
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that the members of its management team will participate...
Cigna Corporation (NYSE:CI) CI is set to report first-quarter 2021 results on May 7, before the opening bell.In the fourth quarter of 2020, the company’s earnings of $3.51...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Neutral | Neutral | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 141.92 | 144.75 | 141.85 | -3.45 | -2.37% | 56.82M | NASDAQ | |||
| 340.00 | 349.60 | 338.94 | -13.58 | -3.84% | 12.06M | NASDAQ | |||
| 2,708.80 | 2,781.90 | 2,707.40 | -112.6 | -3.99% | 1.21M | NASDAQ | |||
| 447.21 | 457.50 | 446.62 | -13.35 | -2.90% | 1.21M | NASDAQ | |||
| 385.66 | 403.14 | 376.03 | -23.18 | -5.67% | 11.26M | NASDAQ | |||
| 206.98 | 214.11 | 206.65 | -9.62 | -4.44% | 21.22M | NASDAQ | |||
| 168.03 | 169.59 | 167.11 | -1.62 | -0.95% | 1.19M | NASDAQ | |||
| 182.20 | 190.65 | 181.15 | -7.28 | -3.84% | 1.04M | NYSE | |||
| 150.46 | 153.05 | 148.87 | +0.28 | +0.19% | 16.00M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 98.34 | 101.07 | 98.28 | -2.92 | -2.88% | 2.35M | NYSE | |||
| 145.68 | 147.50 | 145.50 | -2.36 | -1.59% | 5.46M | NYSE | |||
| 42.86 | 43.10 | 42.43 | -0.71 | -1.63% | 16.11M | NYSE | |||
| 18.10 | 18.10 | 17.57 | +0.15 | +0.84% | 18.98M | NYSE | |||
| 165.87 | 169.29 | 165.83 | -1.11 | -0.66% | 6.80M | NYSE |
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.